FI962976A0 - Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare - Google Patents

Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare

Info

Publication number
FI962976A0
FI962976A0 FI962976A FI962976A FI962976A0 FI 962976 A0 FI962976 A0 FI 962976A0 FI 962976 A FI962976 A FI 962976A FI 962976 A FI962976 A FI 962976A FI 962976 A0 FI962976 A0 FI 962976A0
Authority
FI
Finland
Prior art keywords
galukoma
blocker
beta
compositions
treatment
Prior art date
Application number
FI962976A
Other languages
English (en)
Finnish (fi)
Other versions
FI962976A (sv
Inventor
Yusuf Ali
Rajni Jani
George R Mccarty
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Publication of FI962976A publication Critical patent/FI962976A/sv
Publication of FI962976A0 publication Critical patent/FI962976A0/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI962976A 1994-01-28 1996-07-26 Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare FI962976A0 (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18828494A 1994-01-28 1994-01-28
US08/334,512 US5554367A (en) 1984-10-31 1994-11-04 Compositions for treatment of glaucoma
PCT/US1995/001017 WO1995020378A1 (en) 1994-01-28 1995-01-24 Compositions for treatment of glaucoma comprising pilocarpine and a beta-blocker

Publications (2)

Publication Number Publication Date
FI962976A FI962976A (sv) 1996-07-26
FI962976A0 true FI962976A0 (sv) 1996-07-26

Family

ID=26883909

Family Applications (1)

Application Number Title Priority Date Filing Date
FI962976A FI962976A0 (sv) 1994-01-28 1996-07-26 Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare

Country Status (9)

Country Link
US (1) US5554367A (sv)
EP (1) EP0741563A1 (sv)
JP (1) JP2854418B2 (sv)
AU (1) AU688854B2 (sv)
CA (1) CA2181929C (sv)
FI (1) FI962976A0 (sv)
MX (1) MX9603060A (sv)
NO (1) NO963130D0 (sv)
WO (1) WO1995020378A1 (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6335335B2 (en) 1997-11-05 2002-01-01 Senju Pharmaceutical Co., Ltd. Prolonged-action eye drop
EP1029537B1 (en) * 1997-11-05 2008-02-20 Senju Pharmaceutical Co., Ltd. Sustained release eyedrops
WO2000024425A1 (en) 1998-10-27 2000-05-04 Alcon Laboratories, Inc. Preservative system for topically administrable pharmaceutical compositions
ES2210023T3 (es) * 1999-11-30 2004-07-01 Alcon, Inc. Uso de antagonistas de adrenoceptores neta para la fabricacion de un medicamento para el tratamiento de trastornos de la retina.
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US20050031652A1 (en) * 2003-02-25 2005-02-10 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050147584A1 (en) * 2004-01-05 2005-07-07 Allergan, Inc. Compositions and methods comprising memantine and polyanionic polymers
US20050106321A1 (en) * 2003-11-14 2005-05-19 Molecular Imprints, Inc. Dispense geometery to achieve high-speed filling and throughput
US20050277698A1 (en) * 2004-01-05 2005-12-15 Hughes Patrick M Memantine delivery to the back of the eye
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
CA2671613C (en) * 2006-12-05 2018-07-03 The Royal Institution For The Advancement Of Learning/Mcgill University Methods of use of trk receptor modulators
HUE029400T2 (en) * 2010-05-19 2017-03-28 Astellas Pharma Inc Pharmaceutical composition containing Solifenacin
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
US4342783A (en) * 1980-06-30 1982-08-03 Synthelabo Anti-glaucoma agent
US4474751A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4911920A (en) * 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2601247A1 (fr) * 1986-07-09 1988-01-15 Merk Sharp Dohme Chibret Labor Combinaison d'agents beta-bloquants et de pilocarpine.
US5182102A (en) * 1991-07-12 1993-01-26 Alcon Laboratories, Inc. Anti-glaucoma compositions
AU666957B2 (en) * 1992-08-28 1996-02-29 Alcon Laboratories, Inc. Use of certain anionic surfactants to enhance antimicrobial effectiveness of ophthalmic compositions

Also Published As

Publication number Publication date
NO963130L (no) 1996-07-26
AU1607495A (en) 1995-08-15
MX9603060A (es) 1997-03-29
FI962976A (sv) 1996-07-26
WO1995020378A1 (en) 1995-08-03
US5554367A (en) 1996-09-10
AU688854B2 (en) 1998-03-19
NO963130D0 (no) 1996-07-26
JP2854418B2 (ja) 1999-02-03
EP0741563A1 (en) 1996-11-13
CA2181929A1 (en) 1995-08-03
CA2181929C (en) 1998-11-03
JPH09505604A (ja) 1997-06-03

Similar Documents

Publication Publication Date Title
FI971969A (sv) Kompositioner för behandling av hemorrojder och användningsmetod
FI970918A0 (sv) Föreningar och förfarande för behandling av cancer
FI955051A (sv) Heterocykliska föreningar och framställning och användning av desamma
FI952926A0 (sv) Förfaranden för behandling och förebyggande av allFörfaranden för behandling och förebyggande av allergies ergies
FI971171A (sv) Kompositioner och förfaranden för behandling av inflammationssjukdomar uppkomna av mastcell
FI935154A0 (fi) Foerfarande och anordning foer estimering av signalviktparametrar i en mottagare
FI990171A0 (sv) Nya föreningar och kompositioner för behandling av sjukdomar beroende av tryptasaktivitet
FI972037A (sv) Förbättrat förfarande för framställning av ätbara förpackningar och kompositioner för dessa
FI934839A0 (fi) Foerfarande och anordning foer aoterstaellning av klockan i en skillnadsmottagare
FI971750A0 (sv) Kompositioner och behandling för multipel sclerosis
FI972245A (sv) Mesomonojodsubstituerade tetramakrocykliska föreningar samt förfarande för framställning och användning därav
FI962976A0 (sv) Kompositioner för behandling av galukom innehållande pilokarpin och beta-spärrare
FI960483A (sv) Föränderlig sammansättning och förfaranden för användning av denna
FI931161A (fi) Kompositioner innehaollande estrar av karboxylhaltiga interpolymerer och anvaendning av dessa
FI933540A (fi) Foerfarande och anordning foer vaermebehandling av en matprodukt i en aongatmosfaer
FI972306A (sv) Substituerade 2-arylkarbonyloximetyl-1,2,5-tiadiazolidin-3-oni-1,1-diozid-derivat och dessa innehållande kompositioner och förfaranden för deras användning
FI953087A (sv) Behandling av cellulosaämne och kompositioner för den
FI945945A0 (fi) Foerfarande och anordning foer uppslamning av finfoerdelade aemnen i vaetska
FI935775A0 (fi) Foerfarande och anordning foer gloedgning i kontinuerligt faelt av amorfa metallkaernor foer transformatorer
FI931277A0 (fi) Foerfarande foer koncentrering av processvatten och foer rening av avgaser
FI965146A (sv) Förbättrade förfaranden för bestämmande och reglering av prolaktinens dagliga rytm
FI972307A (sv) 2-(2,3,5,6-tetrafluor-4-pyridyl)1,2,5-tiadiazolidin-3-oni-1,1-dioxider och dessa innehållande kompositioner och förfarande för deras användning
FI971378A0 (sv) Förfaranden och mellanprodukter för framställning av 3-aminobenso(b)azepinoner
FI942331A (sv) Biocidiska kompositioner och användning av dessa
FI944183A0 (fi) TDMA-mottagare och foerfarande foer styrning av TDMA-mottagare